KhanSUTalluriSRiazH, et al.A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. Eur J Prev Cardiol2018; 25: 844–853.
FerenceBAGinsbergHNGrahamI, et al.Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J2017; 38: 2459–2472.
4.
FerenceBAKasteleinJJPGinsbergHN, et al.Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA2017; 318: 947–956.
5.
SilvermanMGFerenceBAImK, et al.Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA2016; 316: 1289–1297.
6.
BallantyneCMLaufsURayKK, et al.Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol2019.
7.
RidkerPMMacFadyenJLibbyP, et al.Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol2010; 106: 204–209.
8.
RidkerPMEverettBMThurenT, et al.Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med2017; 377: 1119–1131.
9.
RayKKBaysHECatapanoAL, et al.Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med2019; 380: 1022–1032.
10.
GoldbergAC. Efficacy and safety of bempedoic acid added to maximally tolerated statins in patients with hypercholesterolemia and high cardiovascular risk: The CLEAR Wisdom trial, New Orleans, USA: American College of Cardiology, 2019.
11.
GrundySMStoneNJBaileyAL, et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol2019; 73: 3168–3209.
12.
KaziDSPenkoJCoxsonPG, et al.Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA2017; 318: 748–750.
